1. Neuronal Signaling
  2. Amyloid-β


Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Amyloid-β Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-B0988
    Deferoxamine mesylate Inhibitor
    Deferoxamine mesylate is an iron chelator, and effectively reduces oxidative stress and neuronal death.
  • HY-19370
    FPS-ZM1 Inhibitor
    FPS-ZM1 is a high-affinity RAGE-specific inhibitor that blocks A(beta) binding to the V domain of RAGE with Ki of 25 (plusmn) 5 nM in RAGE-transfected CHO cells.
  • HY-10009
    Semagacestat Inhibitor
    Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50 of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM.
  • HY-N0009
    Geniposide Antagonist
    Geniposide is an iridoid glucoside extracted from Gardenia jasminoides Ellis fruits; exhibits a varity of biological activities such as anti-diabetic, antioxidative, antiproliferative and neuroprotective activities.
  • HY-15374
    Frentizole Inhibitor
    Frentizole, an FDA-approved immunosuppressive drug, is a novel inhibitor of the A(beta)-ABAD interaction.
  • HY-19771
    amyloid P-IN-1 Inhibitor
    pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer(acute)s disease, type 2 diabetes mellitus and osteoarthritis.
  • HY-18292
    ARN2966 Inhibitor
    ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of A(beta).
  • HY-14533
    K 01-162 Inhibitor
    K 01-162 (K162) binds and destabilizes A(beta)O ((beta)-amyloid), with an EC50 of 80 nM.
  • HY-N0615
    Notoginsenoside R1 Inhibitor
    Notoginsenoside R1, the main bioactive component in panaxnotoginseng, is reported have some neuronal protective, antihypertensive effects.
  • HY-14602
    Tramiprosate Inhibitor
    Tramiprosate is a small, orally-administered compound that binds to soluble A(beta) and reduces amyloid aggregation and subsequent deposition.
  • HY-50900
    gamma-Secretase Modulators Inhibitor
    gamma-Secretase Modulators (Amyloid-(beta) production inhibitor) is a Amyloid-(beta) production inhibitor. gamma-Secretase Modulators is useful for Alzheimer(acute)s disease.
  • HY-N0695
    Schisantherin B Inhibitor
    Schisantherin B is a natural product.
  • HY-B0491A
    Carbazochrome sodium sulfonate Activator
    Carbazochrome(AC-17) is an antihemorrhagic agent.